A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A
- PMID: 19937483
- DOI: 10.1007/s12185-009-0450-y
A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A
Abstract
Discrepancies between low levels of FVIII:C and clinical symptoms in severe hemophilia A are well-known. We have recently demonstrated that levels of FVIII:C < 0.2 IU/dl were consistent with clinical phenotype by clot waveform analysis, suggesting that precise measurement of very low levels of FVIII:C was clinically important. Thrombin generation tests (TGTs) triggered by tissue factor (TF) have been recently utilized to monitor coagulation function in hemophilia A. We examined whether TGT was useful for evaluating hemophilia A patients with very low levels of FVIII:C. TGTs in 40 hemophilia A plasmas with FVIII:C < 0.2-17 IU/dl (measured by clot waveform analysis using MDA-II) were performed using TF and/or ellagic acid (ELG). The lagtime in ELG-TGT at very low levels of FVIII:C was shortened dose-dependently, whilst this parameter in TF-TGT was not significantly affected. Other parameters (endogenous thrombin potential, peak thrombin, time to peak) correlated with FVIII:C levels to some extent in both assays (r = 0.4-0.7). Using a TF/ELG mixture in TGT, however, the correlation coefficients increased to ~0.85. TGT parameters correlated well with levels of FVIII:C > 0.2 IU/dl, although the lagtime was not especially informative. We conclude that modified TGT, using a TF/ELG mixture as the trigger, is useful for monitoring coagulation function at very low levels of FVIII:C in hemophilia A.
Similar articles
-
A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.Int J Hematol. 2020 Nov;112(5):621-630. doi: 10.1007/s12185-020-02959-x. Epub 2020 Aug 3. Int J Hematol. 2020. PMID: 32748217
-
Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A.Indian J Pathol Microbiol. 2021 Jan-Mar;64(1):117-122. doi: 10.4103/IJPM.IJPM_336_19. Indian J Pathol Microbiol. 2021. PMID: 33433420
-
Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A.Haemophilia. 2017 Sep;23(5):e427-e435. doi: 10.1111/hae.13266. Epub 2017 Jul 27. Haemophilia. 2017. PMID: 28750470
-
New assays for monitoring haemophilia treatment.Haemophilia. 2008 Jul;14 Suppl 3:83-92. doi: 10.1111/j.1365-2516.2008.01737.x. Haemophilia. 2008. PMID: 18510527 Review.
-
[Factor VIII assays in treated hemophilia A patients].Ann Biol Clin (Paris). 2019 Feb 1;77(1):53-65. doi: 10.1684/abc.2019.1413. Ann Biol Clin (Paris). 2019. PMID: 30799298 Review. French.
Cited by
-
The in vitro cross-reactivity and blood coagulation potential of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A.Int J Hematol. 2025 Jan;121(1):45-55. doi: 10.1007/s12185-024-03854-5. Epub 2024 Oct 30. Int J Hematol. 2025. PMID: 39476173 Free PMC article.
-
High levels of factor VIII activity in patients with acquired hemophilia A in remission are associated with unusually low coagulation potentials.Int J Hematol. 2023 May;117(5):669-677. doi: 10.1007/s12185-022-03528-0. Epub 2023 Jan 6. Int J Hematol. 2023. PMID: 36607560
-
Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor.Int J Hematol. 2014;99(5):577-87. doi: 10.1007/s12185-014-1572-4. Epub 2014 Apr 1. Int J Hematol. 2014. PMID: 24687919
-
CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.Sci Rep. 2017 Jun 23;7(1):4159. doi: 10.1038/s41598-017-04625-5. Sci Rep. 2017. PMID: 28646206 Free PMC article.
-
A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity.Int J Hematol. 2017 Feb;105(2):174-183. doi: 10.1007/s12185-016-2108-x. Epub 2016 Oct 11. Int J Hematol. 2017. PMID: 27730530
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous